Most Cancer Treatments Are Ineffective those Suffering with Mesothelioma, However Gene Therapy Offers a Beneficial Treatment
Oncologists and other cancer doctors decide what kind of treatment to pursue for a patient. There are numerous options. There exists no universal treatment regimen for pleural mesothelioma cancer victims. This is due to the cancers high mortality rate, rareness, low treatment success rate, and small number of studies to provide meaningful statistics.
Mesothelioma patients have historically had a bleak outlook, but doctors have recently made progress. Customary treatments for cancer are surgery (removing the tumor and the tissue that surrounds it), chemotherapy (poisoning cancerous cells) and radiation (killing cancer cells with radiation) There are problems with all three. Traditional radiation therapy has not worked well with mesothelioma patients. Researchers are looking for ways of aiming radiation directly at the tumor in hopes that this will result in less damage to healthy tissue.
Surgery takes out the mesothelial cancerous tissue around the tumor. The surgery is difficult and challenging, with unknown effects or benefits to patients. The usual chemotherapy cocktails effective on other cancers are not effective on mesothelioma, and combinations of chemotherapy agents have been tried, but without much success. As with radiation, research is going toward controlling the physical location of the treatment with emphasis on the pleural cavity.
The high-mortality rate for mesothelioma patients means cutting-edge techniques for cancer are tried out. These techniques include a biologic therapy called the agent interleukin 2 and anti-angiogenesis drugs like thalidomide. A new drug that has shown results in improving survival is pemetrexed (brand name Alimta).
Considered by oncologists is where the tumor is located, what stage the mesothelioma is in, and the age and health of the patient. Two exotic ways of attacking mesothelioma are gene therapy and photodynamic therapy. Patients afflicted with mesothelioma are benefitting in these clinical trials.
